checkAd
    Madrigal Pharmaceuticals Aktie
    193,05
     
    EUR
    -0,85 %
    -1,65 EUR
    Letzter Kurs 10:08:22 Tradegate
    193,05
     
    EUR
    32 STK
    Geldkurs 11:52:48
    195,55
     
    EUR
    31 STK
    Briefkurs 11:52:48
    ISIN: US5588681057 · WKN: A2APCZ · SYM: YDO1 · USA

    Neueste Nachrichten

    Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
    07.05.24 · globenewswire · Madrigal Pharmaceuticals
    Madrigal Statement on the Passing of Dr. Stephen Harrison
    24.04.24 · globenewswire · Madrigal Pharmaceuticals
    Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
    23.04.24 · globenewswire · Madrigal Pharmaceuticals
    Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    16.04.24 · globenewswire · Madrigal Pharmaceuticals
    Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
    09.04.24 · globenewswire · Madrigal Pharmaceuticals
    Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    03.04.24 · globenewswire · Madrigal Pharmaceuticals
    Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
    19.03.24 · globenewswire · Madrigal Pharmaceuticals
    Madrigal Pharmaceuticals Announces Proposed Public Offering
    18.03.24 · globenewswire · Madrigal Pharmaceuticals
    Madrigal +25%: SD-Tipp betritt Multimilliarden-US$-Markt!
    15.03.24 · Sharedeals · Madrigal Pharmaceuticals
    Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
    14.03.24 · globenewswire · Madrigal Pharmaceuticals
    Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    06.03.24 · globenewswire · Madrigal Pharmaceuticals
    Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
    05.03.24 · globenewswire · Madrigal Pharmaceuticals